Functional diversity among 5-substituted nicotine analogs; in vitro and in vivo investigations

被引:15
作者
Dukat, M
Damaj, IM
Young, R
Vann, R
Collins, AC
Marks, MJ
Martin, BR
Glennon, RA
机构
[1] Virginia Commonwealth Univ, Dept Med Chem, Sch Pharm, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
[3] Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA
关键词
nicotinic receptor; (-)-nicotine; 5-bromonicotine; 5-methoxynicotine; in vitro model; in vivo model;
D O I
10.1016/S0014-2999(01)01570-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two 5-substituted derivatives of nicotine (nicotinic acetylcholine receptor: K-i = 2.4 nM) were synthesized and evaluated: 5-bromonicotine (K-i = 6.9 nM) and 5-methoxynicotine (K-i = 14.3 nM). Despite their high affinity, neither 5-bromonicotine nor 5-methoxynicotine mimicked nicotine in producing antinociceptive (tail-flick, hotplate), hypolocomotor, or hypothermic effects in mice. Neither agent antagonized the hypolocomotor actions of nicotine, whereas 5-methoxynicotine, but not 5-bromonicotine, antagonized the antinociceptive (tail-flick) activity of nicotine in a dose-related manner. In tests of stimulus generalization using rats trained to discriminate 0.6 mg/ka of ( -)-nicotine from vehicle, 5-bromonicotine substituted for nicotine. Further evaluation of 5-bromonicotine indicated that it might be a partial agonist at alpha4beta2 receptors (stimulation of Rb- efflux; alpha4beta2 receptors expressed in oocytes) and at alpha3-containing nicotinic acetylcholine receptors (synaptosomal dopamine release). Thus, 5-bromonicotine might be acting as a partial agonist at alpha4beta2 receptors and/or some of its effects might be related to interactions with non-alpha4beta2 receptors. Clearly, the effects of 5-bromonicotine and 5-methoxynicotine are different from those of nicotine, and from one another. These actions demonstrate that substitution at the 5-position of nicotine exerts a profound influence on the pharmacological profile as well as agonist/antagonist properties of nicotine. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:171 / 180
页数:10
相关论文
共 39 条
  • [1] OPTICALLY PURE (+)-NICOTINE FROM (+/-)-NICOTINE AND BIOLOGICAL COMPARISONS WITH (-)-NICOTINE
    ACETO, MD
    MARTIN, BR
    UWAYDAH, IM
    MAY, EL
    HARRIS, LS
    IZAZOLACONDE, C
    DEWEY, WL
    BRADSHAW, TJ
    VINCEK, WC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1979, 22 (02) : 174 - 177
  • [2] Arneric S. P., 1998, NEURONAL NICOTINIC R
  • [3] Atwell L., 1978, LAB ANIM, V7, P42
  • [4] NEW METHOD FOR METHYLATION OF AMINES
    BORCH, RF
    HASSID, AI
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1972, 37 (10) : 1673 - &
  • [5] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [6] Nicotinic receptors at the amino acid level
    Corringer, PJ
    Le Novère, N
    Changeux, JP
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2000, 40 : 431 - 458
  • [7] (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y): A novel anti-Parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors
    Cosford, NDP
    Bleicher, L
    Herbaut, A
    McCallum, JS
    Vernier, JM
    Dawson, H
    Whitten, JP
    Adams, P
    ChavezNoriega, L
    Correa, LD
    Crona, JH
    Mahaffy, LS
    Menzaghi, F
    Rao, TS
    Reid, R
    Sacaan, AI
    Santori, E
    Stauderman, KA
    Whelan, K
    Lloyd, GK
    McDonald, IA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (17) : 3235 - 3237
  • [8] D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
  • [9] DELEAN A, 1978, AM J PHYSIOL, V235, P97
  • [10] DEWEY WL, 1970, J PHARMACOL EXP THER, V175, P435